Comparative Pharmacology
Head-to-head clinical analysis: FERRIC CITRATE versus PHOSLO GELCAPS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERRIC CITRATE versus PHOSLO GELCAPS.
FERRIC CITRATE vs PHOSLO GELCAPS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferric citrate dissociates to provide ferric iron, which binds dietary phosphate in the gastrointestinal tract, forming insoluble ferric phosphate that is excreted in feces, thereby reducing serum phosphate levels. It also provides iron for erythropoiesis.
Calcium acetate binds dietary phosphate in the gastrointestinal tract, forming insoluble calcium phosphate complexes that are excreted in feces, thereby reducing serum phosphate levels.
1-2 tablets (210-420 mg elemental iron) orally three times daily with meals.
Oral: One to two capsules (668-1336 mg calcium acetate) three times daily with meals, titrated to maintain serum phosphate between 3.5-5.5 mg/dL, maximum 4 capsules per meal.
None Documented
None Documented
Approximately 6 hours for absorbed iron; clinical effect on serum phosphate occurs within 1–2 weeks.
Not applicable; calcium is a physiologic ion with dynamic regulation; steady-state serum calcium is maintained by homeostatic mechanisms. In overdose, serum calcium half-life is approximately 3-4 hours.
Primarily fecal as unabsorbed iron (≥90%); minimal renal excretion (<1%) of absorbed iron.
Primarily fecal as unabsorbed calcium; renal excretion accounts for <1% of absorbed dose proportional to glomerular filtration rate.
Category C
Category C
Phosphate Binder
Phosphate Binder